These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 8993943)

  • 1. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
    Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Pehlivanidis AN; Kontopoulos AG
    J Cardiovasc Risk; 2002 Feb; 9(1):33-9. PubMed ID: 11984215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
    Bredie SJ; Westerveld HT; Knipscheer HC; de Bruin TW; Kastelein JJ; Stalenhoef AF
    Neth J Med; 1996 Aug; 49(2):59-67. PubMed ID: 8824106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E; Dejager S; Chapman MJ
    Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
    Zambón D; Ros E; Rodriguez-Villar C; Laguna JC; Vázquez M; Sanllehy C; Casals E; Sol JM; Hernández G
    Metabolism; 1999 Jan; 48(1):47-54. PubMed ID: 9920144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC; de Valois JC; van den Ende B; Wouter ten Cate J; Kastelein JJ
    Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
    Leonhardt W; Pfützner A; Müller J; Pietzsch J; Forst T; Karagiannis E; Lübben G; Hanefeld M
    Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.
    Calabresi L; Donati D; Pazzucconi F; Sirtori CR; Franceschini G
    Atherosclerosis; 2000 Feb; 148(2):387-96. PubMed ID: 10657575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia.
    de Graaf J; Demacker PN; Stalenhoef AF
    Neth J Med; 1993 Dec; 43(5-6):254-61. PubMed ID: 8107933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
    Chapman MJ; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
    Hernández-Mijares A; Lluch I; Vizcarra E; Martínez-Triguero ML; Ascaso JF; Carmena R
    Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):1-6. PubMed ID: 10812581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
    Nestel P; Simons L; Barter P; Clifton P; Colquhoun D; Hamilton-Craig I; Sikaris K; Sullivan D
    Atherosclerosis; 1997 Mar; 129(2):231-9. PubMed ID: 9105566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.
    Vázquez M; Zambón D; Hernández Y; Adzet T; Merlos M; Ros E; Laguna JC
    Br J Clin Pharmacol; 1998 Mar; 45(3):265-9. PubMed ID: 9517370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.